22 Aug 2025 The current Alzheimer’s disease therapeutic antibodies carry a sizable risk of ARIA, especially for APOE4 carriers. Researchers believe the future of amyloid immunotherapies lies in targeted brain delivery that bypasses the larger blood vessels prone to this side effect, and several companies are working on this. At the Alzheimer’s Association International Conference, […]
Washington, DC -July 28, 2025 –The Global Alzheimer’s Platform Foundation® (GAP), an international leader in accelerating clinical trials and improving recruitment, announced a collaboration with Genentech, a member of the Roche Group, to expand access to clinical trials for communities underrepresented in Alzheimer’s research. This partnership will leverage the combined expertise of GAP’s Site Alliance […]
Washington D.C., Feb. 18, 2025 – The Global Alzheimer’s Platform Foundation® (GAP) is pleased to welcome Roche to the Bio-Hermes-002 study. This collaboration will enhance this unique, observational platform study that compares blood-based and digital biomarkers across a broad range of clinical cognitive conditions, MRI and PET images as well as numerous races and ethnicities […]